Omicron-Specific Pfizer Vaccine's Clinical Trials Begin To Test Efficiency and Safety

The new Omicron-specific Pfizer vaccine is now preparing to start its clinical trials. The upcoming laboratory tests of Pfizer and BioNTech are expected to observe and confirm the efficiency and safety of the modified medicine.

Omicron-Specific Pfizer Vaccine's Clinical Trials Begin To Test Efficiency and Safety
Vials of the Pfizer/BioNTech Covid-19 vaccine are seen during a vaccination clinic at the Sir Ludwig Guttmann Health and Wellbeing Centre on December 15, 2020 in Stratford, England. After rolling out the vaccine to dozens of "hub" hospitals last week, the NHS is now enlisting several hundred primary care practices in its covid-19 vaccination campaign. Photo by Leon Neal/Getty Images
(Photo : Photo by Leon Neal/Getty Images)

Recently, Pfizer explained that it is working on a redesigned version of its COVID-19 vaccine so that the new Omicron variant can be neutralized.

After confirming the development of this new medicine, the giant health firm provided its estimated arrival date. Tech Times previously reported that the redesigned Pfizer vaccine might arrive around March.

This health innovation is currently essential, especially since Omicron is just one of the latest variants of COVID-19. The other one is Deltracron, which is a combination of Omicron and Delta strains.

Omicron-Specific Pfizer Vaccine's Clinical Trials

According to NBC News' latest report, Pfizer is planning to enroll 1,420 health individuals who are around between 18 to 55 years old.

Omicron-Specific Pfizer Vaccine's Clinical Trials Begin To Test Efficiency and Safety
A member of staff poses with a phial of Pfizer-BioNTech Covid-19 vaccine at a vaccination health centre on the first day of the largest immunisation programme in the UK's history on December 8, 2020 in Cardiff, United Kingdom. Wales joined the other UK nations in rolling out the covid-19 vaccine on Tuesday, a rare moment of coordination after months of disjointedness in the four nations' pandemic response. Photo by Justin Tallis - Pool / Getty Images

The medical company announced that the clinical trials would evaluate the safety of the new vaccine and its capability to generate a strong immune response against the new COVID-19 virus.

Aside from this, Pfizer also explained that the participants would be divided into three groups. These include vaccinated, unvaccinated, and fully vaccinated who received booster shots.

Once the laboratory tests for Pfizer's new vaccine begin, health experts will use the gathered information to know if the individuals in each group need to have one, two, or three doses of the modified medicine.

Pfizer Vaccine for Kids Still Not FDA Authorized

As of the moment, Pfizer's COVID-19 vaccine for kids below five years old is still not authorized by the Food and Drug Administration.

Dr. Anthony Fauci, the current White House Chief Medical Advisor, hopes that the FDA will soon allow this COVID-19 medicine.

"My hope is that it's going to be within the next month or so and not much later than that, but I can't guarantee that," said Fauci via CNBC.

He added that it will still depend on the FDA's final decision that Pfizer's vaccine will be used for children below five years old.

For more news updates about Pfizer's vaccine and other COVID-19 related topics, always keep your tabs open here at TechTimes.

This article is owned by TechTimes

Written by: Griffin Davis

ⓒ 2024 TECHTIMES.com All rights reserved. Do not reproduce without permission.
Join the Discussion
Real Time Analytics